- Elanco (ELAN, Financial) reports 93% survival rate for puppies treated with CPMA against canine parvovirus.
- ParvoTrack identifies Texas, Arizona, Georgia, Florida, Illinois, Indiana, and New York as hotspots for parvovirus outbreaks.
- Elanco aims to save 1 million puppies from parvovirus by 2030.
Elanco Animal Health (ELAN) commemorates the second annual National Parvo Awareness Day by highlighting the significant impact of their Canine Parvovirus Monoclonal Antibody (CPMA) treatment. This USDA-conditionally approved treatment has achieved a 93% survival rate for parvo-infected puppies, allowing them to return home an average of 1.87 days sooner than traditional treatments.
Through their innovative real-time outbreak tracking tool, ParvoTrack, thousands of parvovirus cases have been reported nationwide, with Texas, Arizona, Georgia, Florida, Illinois, Indiana, and New York showing the highest outbreak rates. ParvoTrack enables pet owners and veterinarians to self-report cases and receive local outbreak alerts, helping to manage this disease more effectively.
Elanco has an ambitious goal to save 1 million puppies from parvovirus by 2030. The company's efforts have already saved thousands of puppies, with numerous success stories demonstrating the life-saving potential of CPMA treatment.
"Parvo is a devastating disease that not only impacts our pets but also takes an emotional toll on pet owners and veterinarians," said Dr. Chris George, a veterinarian and infectious disease expert at Elanco. "CPMA offers a powerful treatment option with proven results, and we are committed to making it widely available, especially in shelter environments where resources are often strained."
With outbreaks most common during late spring and summer, Elanco encourages clinics and shelters to experience the benefits of CPMA firsthand to help reach their mission of saving 1 million puppies by 2030.
